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ﬁndings in a series of patients with different pleural malignancies and 
healthy controls. 
Methods: A retrospective analyses of 179 patients and 50 healthy 
controls was performed. Seventy-four patient had a conﬁrmed meso-
thelioma, and 110 patients had non small cell lung cancer of whom 56 
with an adenocarcinoma. Soluble Mesothelin Related Protein (SMRP), 
Cyfra 21.1 and Carcino Embrionic Antigen (CEA) were tested in serum 
at diagnosis of patients presenting with a suspected pleural malignancy. 
Results: Cyfra 21.1 was able to discriminate healthy from any thoracic 
malignancy with a sensitivity of 65% and speciﬁcity of 96%. The 
combination of CEA and SMRP was most accurate in differentiating 
mesothelioma from NSCLC (area under receiver operating characteris-
tics curve 0.94, 95% CI 0.90-0.97) and could thus identify 152 of 179 
(85%) cases. 
Conclusions: By using 2 serum markers (CEA and SMRP) we are able 
to discriminate mesothelioma from NSCLC with high sensitivity, while 
Cyfra 21.1 is useful in the discrimination of normal vs. malignancy. 
The relationship between groups and tumor markers by logistic regres-
sion models in univariate and multivariate analyses.
Tumor marker OR 95% CI p-value
Univariate 
Cyfra 21.1 (μgr/l) 1.00 0.99-1.02 0.515
SMRP (nmol/l) 1.64 1.26 <0.001
CEA (μgr/l) 0.45 0.33-0.61 <0.001
Multivariate 
SMRP (nmol/l) 2.02 1.27-3.21 0.003
CEA (μgr/l) 0.43 0.30-0.62 <0.001
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Background: Guidelines for the treatment of MPM do not advocate 
single modality treatment with either radiotherapy or surgery only. 
Since newer and more active chemotherapy became available for 
MPM, combined modality treatment (CMT) for earlier stages of MPM 
has been studied more intensively. We here report on the LLCG phase 
II prospective study of CMT for MPM patients, combining neoadjuvant 
chemotherapy, surgery and postoperative radiotherapy.
Methods: All consecutive MPM patients, candidates for CMT between 
March 2003 and December 2006, were included. Treatment consisted 
of induction chemotherapy with cisplatin 75 mg/m2 and pemetrexed 
500 mg/m2 on day 1 (3 cycles, q 3 wks), extrapleural pleuropneumo-
nectomy (EPP), and radiotherapy (mostly by intensity-modulated radio-
therapy; 54Gy/1.8Gy). Inclusion criteria were: age < 70 years, WHO 
Performance Status ≤1, medically ﬁt for pneumonectomy, staging of 
cT2N2M0 or less for epithelial subtypes, and cT2N1M0 or less for 
other histologic subtypes. All patients underwent thorough staging with 
PET-CT imaging, mediastinoscopy and laparoscopy. 
Results: A total of 29 MPM patients (men/women: 28/1; mean age 
± SD: 57.58 years ± 7.57) were included. Histologic subtypes were: 
epithelial (n=23); desmoplastic (n=1); sarcomatous (n=1); mixed (n=4). 
Five patients were found progressive after induction chemotherapy 
and went off protocol. Twenty patients underwent EPP (left/right EPP: 
7/13; R0/R1 resection 16/4), while 4 patients had an exploratory thora-
cotomy (irresectable MPM due to chest wall or oesophageal invasion). 
Resectability and complete resection rates were 20/24 (83.3%) and 
16/24 (66.6%), respectively. In one patient (male; 50 yrs; cT1bN0M0, 
left side MPM), a complete pathological response was observed. The 
in-hospital postoperative mortality was 2/24 (8.33%) and one re-tho-
racotomy for bleeding needed to be performed. Because 1 patient was 
estimated ineligible for irradiation (unique kidney) and another rapidly 
developed bone metastases, 16 patients ﬁnally started postoperative 
radiotherapy. One patient died just after ending radiotherapy (BOOP) 
and another didn’t complete radiotherapy (small bowel obstruction 
and respiratory infection). At the end, 15/29 patients completed the 
entire CMT protocol. Median survival (after MPM diagnosis) was 9.01 
months for all 29 patients who started CMT and 20.6 months for the 15 
patients who completed CMT, respectively.
Conclusions: This study demonstrates that CMT with neoadjuvant che-
motherapy, EPP and postoperative radiotherapy is feasible in dedicated 
centres and for well-elected MPM patients. The median survival for 
those patients who completed CMT is promising, but longer follow-up 
and validation of these results in future randomized controlled trials 
will be of interest. 
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Background: 18F-Fluorodeoxy glucose positron emission tomography 
(FDG- PET) is a promising tool for evaluating suspected malignancies 
throughout the body. Although there have been a few reports on FDG-
PET for imaging thymic epithelial tumors, its clinical usefulness and 
signiﬁcance are still unclear. The objective of this study was to analyze 
the degree of FDG-uptake in thymic epithelial tumors of different 
WHO histologic subtypes and stages.
Methods: We retrospectively reviewed FDG-PET ﬁndings in 35 
patients with thymic epithelial tumors (25 with thymomas and 10 with 
thymic carcinomas) treated between September 2002 and March 2007 
at Shizuoka Cancer Center. Twenty-three (66%) patients underwent 
surgical resection and the remaining 12 underwent only needle biopsy. 
The histologic subtype was determined according to the WHO clas-
siﬁcation in all 10 thymic carcinomas and 21 resected thymomas. The 
stage was determined according to Masaoka classiﬁcation in all 25 thy-
momas. FDG uptake in tumor using the maximum Standardized Uptake 
